Yesterday was a busy day and ended up being a little crazier than I planned but I am not back in the office and ready to think about some biotech. I did not have a chance to check the market yesterday so I am not sure how it traded but it seems like it is […]
May 19 Biotech Update- The Merger Drama
It was certainly an interesting start to the week in terms of the PFE/AZN drama but the price action outside of those names was somewhat muted (I guess also outside the ITMN move). My point is that outside the names directly related to news, there was nothing significant and more of a trending day (with […]
May 15 Biotech Update- The ASCO Deluge Begins
So there is a lot to talk about with the ASCO abstracts and I will divide this up over a couple of days (I am trying to write quickly to get this out so excuse typos and poor grammar for the next couple of days). In general, I think the sense is that these are […]
May 8- The Biotech Draft
While there are some stock specific pieces of news, I want to do something a little different today in honor of the NFL draft. I am going to draft my top 10 stocks. This is assuming that I have no positions at all, so this is not what I would be buying now but if […]
May 6 Biotech Update- The Slow Week Cotinues
It was another pretty blah day in biotech land. I guess this is making up for all the news we have had the past couple of weeks. As I expected, the biggest news of the days is MRK business update (you can download the slides here) and the early verdict is that they are making […]
May 5 Biotech Update
Really not a lot to talk about today. The sector had a decent morning but news flow was relatively low outside of the PFE call. Even that was a little anti-climatic as it did not really add anything that we did not already know. They made the case that an AZN deal does not destroy […]
May 2 Biotech Update- The Ups and Downs of the Sector
It was a generally good day in terms of news for the sector (with notable exceptions) but the price action was bad. I think this is going to be the probable going forward in that trading will be very choppy and volatile despite positive or negative news. I do not see this trading as changing […]
April 29 Biotech Update- A Day of Steady Progress
The rollercoaster continues as we swing up and down in seemingly ever tighter time frames. In some ways, that seems good in that base building is a messy process with fairly rapid swings. I still think the sector needs the macro environment to be at least neutral in order to really set in a base […]
April 28 Biotech Update- Turning Up the M&A Speculation
It was another interesting and good start to the week (until we got into the usual late morning selling). In fact, it seems like we were just talking about a PFE offer for AZN last Monday (oh, wait we were). Is this the reason that the sector is stronger or are we simply getting an […]
Dissecting the ASCO 2014 abstract titles
Today, the American Society for Clinical Oncology(ASCO) posted a link to the ASCO 2014 meeting planner[LINK]. The planner also includes all of the abstract titles at the meeting. ASCO 2014 is scheduled to take place from May 30th to June 3rd, 2014. Below we list some of our observations on the oral abstracts. We have […]
April 7 Biotech Update- An Active AACR
So a lot to talk about and I will briefly touch on a lot and then expand later this week as I doubt many days will be a busy as today in term of news. The sector had a good morning but we have seen this before and at this point it will not be […]
March 25 Biotech Update- Would it Help to Cry Uncle?
Today certainly started as a better day in the sector but I would be careful of chasing this move. Ideally, we spend time building a base but a day or two of running is possible given the oversold conditions in the space. At this point I would lean towards the sector having put in a […]
March 14 Biotech Update- Seeing Red as Value or the End?
Interesting morning for the sector with the broader market relatively unchanged and the biotech sector selling off hard. Why would this be the case? Is it something fundamental to the sector or just jittery traders dumping unnecessarily? Given the macro uncertainty in the Ukraine it could just be the case that traders are reducing risk […]
March 12 Biotech Update- Ovarian Cancer in the News
The broad sector continues to try and finds its footing, so there is really nothing new on that front. I want to spend this note talking about two companies that I have been receiving questions on the past couple of days. Please keep the questions coming as I want to make sure and touch on […]
Upcoming events for Merck
Members of Chimera Research Group have successfully been trading Merck for the past few months, especially Joe Gantos(@GantosJ). Merck has been one of the strongest big pharmas over the past few month on the heels of pipeline developments. With a new year, we want to provide a road map for what’s to come in the […]
February 25 Biotech Update- Some Upcoming Catalysts
It is another day with the sector trading basically in line with market and the real outperformers/underperformers have news associated with them. At this point the real tension in the sector is between the clear continuation of the rally and the fear/expectation of a larger macro correction that will take the sector down with it. […]
February 10 Biotech Update- A Choppy Start to the Week
It was a choppy and mixed morning with the market and sector looking for direction. There were winners and losers across the sector and market caps. After a large up day, it is not necessarily bad for the market to settle down to digest the move. All of that being said, if I had to […]
February 3 Biotech Update- The Bloodbath Edition
It was another rough day in the market with a familiar pattern- market weak, large cap biotechs outperforming the broader market and small cap biotechs underperforming. It makes sense in that risk off means selling biotechs but large cap biotechs have a valuation buffer in their growing free cash flow. This is not to say […]
January 31 Biotech Update- The Hep-C Competition Heats Up
The market was just a little weak this morning and biotechs responded as one would expect, although despite the sea of red I kept thinking that it could be have been worse. Today was certainly not a good day but the market is starting to provide us some good bargains. There could be a larger […]
January 27 Biotech Update
It is amazing how quickly sentiment can change. Last week I was noting the shifts and the expectations for a correction. This was certainly needed but I think the speed of the move has less to do with fundamentals and more to do with jittery investors. Nobody wants to be the last one to sell, […]
